{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:53:03Z","timestamp":1783745583822,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40256-014-0093-0","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T12:37:05Z","timestamp":1413203825000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Epoprostenol (Veletri\u00ae, Caripul\u00ae): A Review of Its Use in Patients with Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"14","author":[{"given":"Sarah L.","family":"Greig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg L.","family":"Plosker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"issue":"5 Suppl","key":"93_CR1","doi-asserted-by":"crossref","first-page":"1A","DOI":"10.1016\/j.amjcard.2012.12.002","volume":"111","author":"AB Waxman","year":"2013","unstructured":"Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol. 2013;111(5 Suppl):1A\u201316A.","journal-title":"Am J Cardiol."},{"issue":"25 Suppl","key":"93_CR2","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","volume":"62","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42\u201350.","journal-title":"J Am Coll Cardiol."},{"issue":"25 Suppl","key":"93_CR3","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","volume":"62","author":"G Simonneau","year":"2013","unstructured":"Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34\u201341.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"93_CR4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s11906-013-0397-5","volume":"15","author":"X Jiang","year":"2013","unstructured":"Jiang X, Jing ZC. Epidemiology of pulmonary arterial hypertension. Curr Hypertens Rep. 2013;15(6):638\u201349.","journal-title":"Curr Hypertens Rep."},{"issue":"6","key":"93_CR5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","volume":"34","author":"N Galie","year":"2009","unstructured":"Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219\u201363.","journal-title":"Eur Respir J."},{"issue":"122","key":"93_CR6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09059180.00007011","volume":"20","author":"O Sitbon","year":"2011","unstructured":"Sitbon O, Simonneau G. Optimal management of severe pulmonary arterial hypertension. Eur Respir Rev. 2011;20(122):254\u201361.","journal-title":"Eur Respir Rev."},{"issue":"129","key":"93_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09059180.00001713","volume":"22","author":"A Seferian","year":"2013","unstructured":"Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev. 2013;22(129):217\u201326.","journal-title":"Eur Respir Rev."},{"key":"93_CR8","unstructured":"Actelion Pharmaceuticals UK Ltd. UK summary of product characteristics for Veletri, 0.5\u00a0mg, powder for solution for infusion. 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/27736\/SPC . Accessed 29 Sept 2014."},{"key":"93_CR9","unstructured":"Actelion Pharmaceuticals US Inc. Veletri (epoprostenol) for injection: US prescribing information. 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022260s005lbl.pdf . Accessed 29 Sept 2014."},{"key":"93_CR10","unstructured":"Actelion Pharmaceuticals Ltd. Actelion obtains marketing approval for Epoprostenol \u201cACT\u201d in Japan [media release]. http:\/\/www.actelion.com\/en\/our-company\/news-and-events\/index.page?newsId=1678832 . Accessed 18 Feb 2013."},{"issue":"6","key":"93_CR11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.rmed.2010.12.018","volume":"105","author":"Z Safdar","year":"2011","unstructured":"Safdar Z. Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. Respir Med. 2011;105(6):818\u201327.","journal-title":"Respir Med."},{"issue":"7","key":"93_CR12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","volume":"112","author":"LJ Rubin","year":"1990","unstructured":"Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112(7):485\u201391.","journal-title":"Ann Intern Med."},{"issue":"5","key":"93_CR13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296\u2013301.","journal-title":"N Engl J Med."},{"issue":"25 Suppl","key":"93_CR14","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","volume":"62","author":"N Galie","year":"2013","unstructured":"Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D60\u201372.","journal-title":"J Am Coll Cardiol."},{"issue":"1 Suppl","key":"93_CR15","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","volume":"54","author":"RJ Barst","year":"2009","unstructured":"Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S78\u201384.","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"93_CR16","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.healun.2013.08.010","volume":"32","author":"HW Farber","year":"2013","unstructured":"Farber HW, Miller DP, Meltzer LA, et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL registry. J Heart Lung Transplant. 2013;32(11):1114\u201322.","journal-title":"J Heart Lung Transplant."},{"issue":"2","key":"93_CR17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","volume":"137","author":"DB Badesch","year":"2010","unstructured":"Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137(2):376\u201387.","journal-title":"Chest."},{"issue":"2","key":"93_CR18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ahj.2013.08.007","volume":"167","author":"O Sitbon","year":"2014","unstructured":"Sitbon O, Delcroix M, Bergot E, et al. EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J. 2014;167(2):210\u20137.","journal-title":"Am Heart J."},{"key":"93_CR19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/DDDT.S29916","volume":"6","author":"O Lambert","year":"2012","unstructured":"Lambert O, Bandilla D, Iyer R, et al. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted. Drug Des Dev Ther. 2012;6:61\u201370.","journal-title":"Drug Des Dev Ther."},{"key":"93_CR20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/DDDT.S31628","volume":"6","author":"O Lambert","year":"2012","unstructured":"Lambert O, Bandilla D. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Des Dev Ther. 2012;6:235\u201344.","journal-title":"Drug Des Dev Ther."},{"issue":"2","key":"93_CR21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ahj.2013.08.008","volume":"167","author":"KM Chin","year":"2014","unstructured":"Chin KM, Badesch DB, Robbins IM, et al. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014;167(2):218\u201325.e1.","journal-title":"Am Heart J"},{"issue":"1","key":"93_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2009.07.015","volume":"104","author":"KK Mubarak","year":"2010","unstructured":"Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104(1):9\u201321.","journal-title":"Respir Med."},{"issue":"3","key":"93_CR23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/hrt.44.3.254","volume":"44","author":"J Szczeklik","year":"1980","unstructured":"Szczeklik J, Szczeklik A, Nizankowski R. Haemodynamic changes induced by prostacyclin in man. Br Heart J. 1980;44(3):254\u20138.","journal-title":"Br Heart J."},{"issue":"2","key":"93_CR24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","volume":"66","author":"LJ Rubin","year":"1982","unstructured":"Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66(2):334\u20138.","journal-title":"Circulation."},{"issue":"6","key":"93_CR25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-2125.2012.04301.x","volume":"74","author":"LB Nicolas","year":"2012","unstructured":"Nicolas LB, Krause A, Gutierrez MM, et al. Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. Br J Clin Pharmacol. 2012;74(6):978\u201389.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"93_CR26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.clinthera.2013.02.013","volume":"35","author":"LB Nicolas","year":"2013","unstructured":"Nicolas LB, Gutierrez MM, Dingemanse J. Comparative pharmacokinetic, pharmacodynamic, safety, and tolerability profiles of 3 different formulations of epoprostenol sodium for injection in healthy men. Clin Ther. 2013;35(4):440\u20139.","journal-title":"Clin Ther."},{"issue":"12","key":"93_CR27","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/17425255.2010.534458","volume":"6","author":"MC Chaumais","year":"2010","unstructured":"Chaumais MC, Jobard M, Huertas A, et al. Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opin Drug Metab Toxicol. 2010;6(12):1587\u201398.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"1","key":"93_CR28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0022-3565(25)21477-X","volume":"226","author":"AR Brash","year":"1983","unstructured":"Brash AR, Jackson EK, Saggese CA, et al. Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther. 1983;226(1):78\u201387.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"93_CR29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/j.1552-4604.1996.tb04195.x","volume":"36","author":"LD Carlton","year":"1996","unstructured":"Carlton LD, Patterson JH, Mattson CN, et al. The effects of epoprostenol on drug disposition. I: a pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure. J Clin Pharmacol. 1996;36(3):247\u201356.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"93_CR30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/j.1552-4604.1996.tb04196.x","volume":"36","author":"LD Carlton","year":"1996","unstructured":"Carlton LD, Patterson JH, Mattson CN, et al. The effects of epoprostenol on drug disposition. II: a pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure. J Clin Pharmacol. 1996;36(3):257\u201364.","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"93_CR31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12325-013-0029-0","volume":"30","author":"Y Tamura","year":"2013","unstructured":"Tamura Y, Ono T, Fukuda K, et al. Evaluation of a new formulation of epoprostenol sodium in Japanese patients with pulmonary arterial hypertension (EPITOME4). Adv Ther. 2013;30(5):459\u201371.","journal-title":"Adv Ther."},{"issue":"13","key":"93_CR32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/CIRCULATIONAHA.109.865881","volume":"120","author":"KW Jensen","year":"2009","unstructured":"Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation. 2009;120(13):1248\u201354.","journal-title":"Circulation."},{"issue":"Suppl. 57","key":"93_CR33","first-page":"863s","volume":"42","author":"M Delcroix","year":"2013","unstructured":"Delcroix M, Simonneau G, Bergot E, et al. Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension [abstract no. P4080]. Eur Respir J. 2013;42(Suppl. 57):863s\u20134s.","journal-title":"Eur Respir J."},{"key":"93_CR34","unstructured":"GlaxoSmithKline. FLOLAN\u00ae (epoprostenol sodium) for injection: prescribing information. 2011. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020444s018lbl.pdf . Accessed 29 Sept 2014."},{"key":"93_CR35","doi-asserted-by":"crossref","unstructured":"Farber HW, Frantz RP, Schilz R, et al. The PROSPECT registry: study design, patient characteristics, and treatment patterns [abstract no. A2499]. Am J Respir Crit Care Med. 2012;185.","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2499"},{"issue":"7","key":"93_CR36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.healun.2014.02.019","volume":"33","author":"G Simonneau","year":"2014","unstructured":"Simonneau G, Rubin LJ, Galie N, et al. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014;33(7):689\u201397.","journal-title":"J Heart Lung Transplant."},{"issue":"6","key":"93_CR37","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","volume":"43","author":"O Sitbon","year":"2014","unstructured":"Sitbon O, Jais X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691\u20137.","journal-title":"Eur Respir J."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-014-0093-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-014-0093-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-014-0093-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:45:07Z","timestamp":1746416707000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-014-0093-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1007\/s40256-014-0093-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}